The five-year, $2.5 million study aims to reduce the burdens of prostate cancer screening by substantially enhancing prostate cancer risk evaluation and reducing unnecessary and invasive prostate biopsies to improve the quality of life of men undergoing prostate cancer evaluation. Shown left-to-right are Sylvester investigators Sanoj Punnen, M.D.; Sandra Gaston, Ph.D.; and Alan Pollack, M.D., Ph.D.